Abstract
Estrone sulfatase (ES) is a membrane-bound enzyme that is responsible for maintaining high levels of estrogens in breast cancer cells. This may be due to the conversion of estrone-sulfate into estrone by estronesulfatase, which acts as a pool of potentially available estrogens. There is now abundant evidence that estrogens have a pivotal role in the growth and development of hormone-dependent breast cancer. Thus, inhibitors of ES should have considerable therapeutic potential for the treatment of hormone-dependent breast cancer. Recently, a large number of sulfamate-based steroidal and non-steroidal ES inhibitors have been developed. The sulfamate moiety is believed to be involved in the irreversible inhibition of ES. In the present paper, we have undertaken quantitative structure-activity relationships for different series of non-steroidal sulfamate-based compounds in order to understand the chemical-biological interactions governing their inhibitory potency against ES. QSAR results have shown that the inhibitory potency against ES for these nonsteroidal sulfamate-based compounds is largely dependent on their hydrophobicity and molar refractivity.
Keywords: breast cancer, estrone sulfatase inhibitors, hydrophobicity, molar refractivity, non-steroidal sulfamates, structureactivity relationships
Letters in Drug Design & Discovery
Title: An Approach Towards the Quantitative Structure-Activity Relationships for Sulfamate-Based Estrone Sulfatase Inhibitors
Volume: 2 Issue: 3
Author(s): Rajeshwar P. Verma
Affiliation:
Keywords: breast cancer, estrone sulfatase inhibitors, hydrophobicity, molar refractivity, non-steroidal sulfamates, structureactivity relationships
Abstract: Estrone sulfatase (ES) is a membrane-bound enzyme that is responsible for maintaining high levels of estrogens in breast cancer cells. This may be due to the conversion of estrone-sulfate into estrone by estronesulfatase, which acts as a pool of potentially available estrogens. There is now abundant evidence that estrogens have a pivotal role in the growth and development of hormone-dependent breast cancer. Thus, inhibitors of ES should have considerable therapeutic potential for the treatment of hormone-dependent breast cancer. Recently, a large number of sulfamate-based steroidal and non-steroidal ES inhibitors have been developed. The sulfamate moiety is believed to be involved in the irreversible inhibition of ES. In the present paper, we have undertaken quantitative structure-activity relationships for different series of non-steroidal sulfamate-based compounds in order to understand the chemical-biological interactions governing their inhibitory potency against ES. QSAR results have shown that the inhibitory potency against ES for these nonsteroidal sulfamate-based compounds is largely dependent on their hydrophobicity and molar refractivity.
Export Options
About this article
Cite this article as:
Verma P. Rajeshwar, An Approach Towards the Quantitative Structure-Activity Relationships for Sulfamate-Based Estrone Sulfatase Inhibitors, Letters in Drug Design & Discovery 2005; 2 (3) . https://dx.doi.org/10.2174/1570180053765093
DOI https://dx.doi.org/10.2174/1570180053765093 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels Predict Response to Gemcitabine in Patients With Biliary Tract Cancer (BTC)
Current Cancer Drug Targets Therapeutic Potential of microRNA Against Th2-associated Immune Disorders
Current Topics in Medicinal Chemistry Caffeine; the Forgotten Potential for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Implications of Nanoscale Based Drug Delivery Systems in Delivery and Targeting Tubulin Binding Agent, Noscapine in Cancer Cells
Current Drug Metabolism Meet Our Editorial Board Member:
Current Drug Targets ATP Non-Competitive Ser/Thr Kinase Inhibitors as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Discovery of Hybrid Purine-quinoline Molecules and Their Cytotoxic Evaluation
Letters in Drug Design & Discovery The Complexity of Aging: Cancer Risk Among Elderly People and Infectious Risk Among Those with Cancer
Anti-Cancer Agents in Medicinal Chemistry Subject Index to Volume 4
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Histone Deacetylase Inhibitors in Cancer Therapy: New Compounds and Clinical Update of Benzamide-Type Agents
Current Topics in Medicinal Chemistry Dendrogenin A: A Mammalian Metabolite of Cholesterol with Tumor Suppressor and Neurostimulating Properties
Current Medicinal Chemistry Reproductive Toxicology of Environmental Toxicants: Emerging Issues and Concerns
Current Pharmaceutical Design High Cytotoxicity and Apoptotic Effects of Natural Bioactive Benzofuran Derivative on the MCF-7 Breast Cancer Cell Line
Combinatorial Chemistry & High Throughput Screening Nanostructures as Promising Tools for Delivery of Antimicrobial Peptides
Mini-Reviews in Medicinal Chemistry ATP-Binding Cassette Transporters at the Blood-Brain Barrier in Ischaemic Stroke
Current Pharmaceutical Design Acridone-based Antitumor Agents: A Mini-review
Anti-Cancer Agents in Medicinal Chemistry Physiology of Immune System: Regulation of Stem Cell Survival
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Prometheus: The Supreme Court Redefines the Patentability of Diagnostic Inventions
Recent Patents on DNA & Gene Sequences CDK Inhibitors: From the Bench to Clinical Trials
Current Drug Targets Assessment of Nutritional Status in Cancer – The Relationship Between Body Composition and Pharmacokinetics
Anti-Cancer Agents in Medicinal Chemistry